LV12125B - CYCLFILINE ROTAMASE ACTIVITIES INHIBITORS - Google Patents

CYCLFILINE ROTAMASE ACTIVITIES INHIBITORS Download PDF

Info

Publication number
LV12125B
LV12125B LVP-98-114A LV980114A LV12125B LV 12125 B LV12125 B LV 12125B LV 980114 A LV980114 A LV 980114A LV 12125 B LV12125 B LV 12125B
Authority
LV
Latvia
Prior art keywords
group
neurological activity
activity
neurological
fluorinated
Prior art date
Application number
LVP-98-114A
Other languages
English (en)
Latvian (lv)
Other versions
LV12125A (lv
Inventor
Joseph P. Steiner
Gregory S. Hamilton
Solomon H. Snyder
Original Assignee
Guilford Pharmaceuticals Inc.
Johns Hopkins University School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc., Johns Hopkins University School Of Medicine filed Critical Guilford Pharmaceuticals Inc.
Publication of LV12125A publication Critical patent/LV12125A/xx
Publication of LV12125B publication Critical patent/LV12125B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LVP-98-114A 1995-11-20 1998-07-16 CYCLFILINE ROTAMASE ACTIVITIES INHIBITORS LV12125B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56068595A 1995-11-20 1995-11-20
PCT/US1996/017677 WO1997018828A1 (en) 1995-11-20 1996-11-15 Inhibitors of cyclophilin rotamase activity

Publications (2)

Publication Number Publication Date
LV12125A LV12125A (lv) 1998-09-20
LV12125B true LV12125B (en) 1998-12-20

Family

ID=24238888

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-114A LV12125B (en) 1995-11-20 1998-07-16 CYCLFILINE ROTAMASE ACTIVITIES INHIBITORS

Country Status (18)

Country Link
US (2) US6444643B1 (es)
EP (1) EP0880358B1 (es)
JP (1) JP3089350B2 (es)
KR (1) KR19990071482A (es)
CN (1) CN1123360C (es)
AT (1) ATE246510T1 (es)
AU (1) AU714482B2 (es)
BR (1) BR9611624A (es)
CA (1) CA2238050C (es)
CZ (1) CZ154098A3 (es)
DE (1) DE69629392T2 (es)
ES (1) ES2206608T3 (es)
LV (1) LV12125B (es)
MX (1) MX9804011A (es)
NO (1) NO982264L (es)
PL (1) PL327994A1 (es)
TR (1) TR199800890T2 (es)
WO (1) WO1997018828A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
PA8442401A1 (es) * 1996-12-09 2000-05-24 Guilford Pharm Inc Inhibidores polipropilos de ciclofilina
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
AU8918998A (en) 1997-08-26 1999-03-16 Wisconsin Alumni Research Foundation Non-immunosuppressive cyclosporins and their use in the prevention and treatmentof hiv infection
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP4350898B2 (ja) 1998-07-01 2009-10-21 デビオファーム・ソシエテ・アノニム 活性の特徴が改善された新規のシクロスポリン
US6030825A (en) * 1998-08-19 2000-02-29 Incyte Pharmaceuticals, Inc. Cyclophilin-type peptidyl-prolyl cis/trans isomerase
JP2002526453A (ja) * 1998-09-23 2002-08-20 キープ，マルカス 選択的なニューロンの放射線保護のためのニューロイムノフィリン類
JP2002541264A (ja) 1999-04-08 2002-12-03 ユーエイビー・リサーチ・ファウンデーション 冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
EP1214293A1 (en) 1999-09-08 2002-06-19 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
MXPA03006666A (es) 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US20030068321A1 (en) * 2001-09-07 2003-04-10 Guilford Pharmaceuticals, Inc. Methods of effecting neuronal activity
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
CN1984670A (zh) * 2004-07-13 2007-06-20 诺瓦提斯公司 治疗阿尔茨海默病的环孢菌素
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ES2373450T3 (es) * 2004-10-01 2012-02-03 Scynexis, Inc. Derivados de ciclosporina sustituidos con 3-éter y 3-tioéter para el tratamiento y la prevención de infección por hepatitis c.
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
JP5322647B2 (ja) * 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
ES2361635T3 (es) 2006-05-19 2011-06-20 Scynexis, Inc. Ciclosporinas para el tratamiento y prevención de trastornos oculares.
JP2009539292A (ja) * 2006-06-02 2009-11-12 ぺリション、クロード、アニー 活性電子の管理
US7576057B2 (en) * 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
NZ584356A (en) 2007-09-26 2011-10-28 Univ Oregon Health & Science Cyclic undecapeptides and derivatives as multiple sclerosis therapies
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
JP5726733B2 (ja) * 2008-07-30 2015-06-03 シクロフィリン ファーマシューティカルズ コープ． 非免疫抑制性シクロスポリン類似体分子
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CA2748389A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
WO2012079172A1 (en) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260468D1 (en) * 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) * 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
EP0296123B1 (en) * 1987-06-19 1994-08-31 Sandoz Ag Cyclic peptolides
US4914188A (en) * 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5284826A (en) * 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5898029A (en) 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤

Also Published As

Publication number Publication date
JPH09143198A (ja) 1997-06-03
AU714482B2 (en) 2000-01-06
DE69629392T2 (de) 2004-06-24
KR19990071482A (ko) 1999-09-27
JP3089350B2 (ja) 2000-09-18
BR9611624A (pt) 1999-06-01
US20030013645A1 (en) 2003-01-16
MX9804011A (es) 1998-09-30
CA2238050A1 (en) 1997-05-29
PL327994A1 (en) 1999-01-04
ATE246510T1 (de) 2003-08-15
CA2238050C (en) 2010-09-28
EP0880358B1 (en) 2003-08-06
EP0880358A1 (en) 1998-12-02
CZ154098A3 (cs) 1998-12-16
WO1997018828A1 (en) 1997-05-29
CN1123360C (zh) 2003-10-08
US6444643B1 (en) 2002-09-03
AU7721096A (en) 1997-06-11
CN1207043A (zh) 1999-02-03
NO982264D0 (no) 1998-05-18
EP0880358A4 (en) 2001-04-18
DE69629392D1 (de) 2003-09-11
LV12125A (lv) 1998-09-20
NO982264L (no) 1998-07-20
ES2206608T3 (es) 2004-05-16
TR199800890T2 (xx) 1998-08-21

Similar Documents

Publication Publication Date Title
EP0880358B1 (en) Inhibitors of cyclophilin rotamase activity
US6245783B1 (en) Method of using neurotrophic sulfonamide compounds
US5801197A (en) Rotamase enzyme activity inhibitors
CN101754769B (zh) 基于具有抗微生物活性的b型羊毛硫抗生素的用途
WO2003070755A2 (fr) Composes et compositions pour le transport de la cyclosporine a travers la barriere hemato-encephalique
CA2281096A1 (en) Method of using neurotrophic carbamates and ureas
WO2005087798A1 (de) An der hydroxylgruppe midifizierte ‘d-ser!8-cyclosporine mit schaltbarer hemmung der proteinphosphatase calzineurin und dadurch gezielter manipulierbarkeit der immunosuppressiven wirkung unter beibehaltung der peptidyl-prolyl-cis-trans-isomerase (ppi) inhibition z.b. zur behandlung von autoimmunerkrankungen
US6242468B1 (en) Carbamate and urea compositions and neurotrophic uses
MXPA01006449A (es) Un agente para tratar el transtorno de la funcion de las celulas visuales.
JP2007532507A (ja) 脳虚血ならびに脳および脊髄傷害の処置のためのサイクロスポリンの使用
US20020013344A1 (en) Rotamas enzyme activity inhibitors
AU713302C (en) Rotamase enzyme activity inhibitors
US20030068321A1 (en) Methods of effecting neuronal activity
MXPA98003356A (es) Inhibidores de la actividad de la enzima rotamasa